Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
416 studies found for:    Open Studies | "Nevus"
Show Display Options
Rank Status Study
21 Recruiting Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects
Conditions: Burn Injury;   Soft Tissue Injury;   Skin Necrosis;   Scars;   Congenital Giant Nevus;   Skin Tumors
Interventions: Other: denovoDerm;   Other: denovoSkin
22 Recruiting Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
Condition: Basal Cell Carcinoma
Intervention: Drug: Vismodegib
23 Recruiting Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Condition: Melanoma
Intervention:
24 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
25 Recruiting Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Conditions: Unresectable Malignant Neoplasm;   Melanoma;   Metastatic Melanoma;   Stage IV Melanoma;   Stage III Melanoma
Intervention: Drug: Pembrolizumab
26 Recruiting A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
Conditions: Advanced Malignancy;   Advanced Solid Tumors;   Cancer;   Oncology;   Oncology Patients;   Tumors;   Melanoma
Interventions: Drug: AMG 232;   Drug: Trametinib;   Drug: Dabrafenib
27 Recruiting Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
Condition: Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies
Intervention: Biological: TRX518
28 Recruiting Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the Size of Sporadic Nodular Basal Cell Carcinomas
Condition: Basal Cell Carcinomas
Interventions: Drug: patidegib gel 2% - cohort 1;   Drug: patidegib gel 4% - cohort 2;   Drug: Vehicle - cohort 1;   Drug: patidegib gel 2% - cohort 3;   Drug: patidegib gel 4% - cohort 4;   Drug: vehicle - cohort 2;   Drug: Vehicle - cohort 3;   Drug: Vehicle - cohort 4
29 Not yet recruiting Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
Conditions: Melanoma and Other Malignant Neoplasms of Skin;   Metastatic Melanoma
Interventions: Drug: Azacitidine;   Drug: Pembrolizumab
30 Recruiting SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Conditions: Metastatic Malignant Neoplasm in the Brain;   Metastatic Malignant Neoplasm in the Spine;   Stage IV Skin Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Radiation: Stereotactic Radiosurgery
31 Recruiting Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
Conditions: Carcinoma, Hepatocellular;   Colorectal Neoplasms;   Melanoma;   Kidney Neoplasms
Interventions: Procedure: Blood samples collection before radiotherapy;   Procedure: Blood samples collection during radiotherapy;   Procedure: Blood samples collection after radiotherapy;   Radiation: Radiotherapy
32 Recruiting To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Conditions: Neuroblastoma;;   Rhabdomyosarcoma;;   Ewing's Sarcoma;;   Ewing's Tumor;;   Sarcoma, Ewing's;;   Sarcomas, Epitheliod;;   Sarcoma, Soft Tissue;;   Sarcoma, Spindle Cell;;   Melanoma;;   Malignant Melanoma;;   Clinical Oncology;;   Oncology, Medical;;   Pediatrics, Osteosarcoma;;   Osteogenic Sarcoma;;   Osteosarcoma Tumor;;   Sarcoma, Osteogenic;;   Tumors;;   Cancer;;   Neoplasia;;   Neoplasm;;   Histiocytoma;;   Fibrosarcoma;;   Dermatofibrosarcoma
Intervention: Drug: nab-paclitaxel
33 Recruiting Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
Conditions: Tumors;   Malignant Melanoma;   Hematological Malignancies;   Myelogenous Leukemia, Chronic;   Leukemia, Lymphoblastic, Acute
Interventions: Procedure: Immunoablative Hematopoietic PBSC Transplant;   Procedure: Busulfan pharmacokinetics;   Radiation: Central Nervous System (CNS) prophylaxis radiation
34 Not yet recruiting SAbR-induced Innate Immunity
Conditions: Urothelial Carcinoma;   Melanoma;   Cervical Carcinoma in Situ
Intervention: Radiation: SAbR Treatment of Lesions
35 Recruiting Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
Condition: Melanoma
Interventions: Biological: DS-8273a;   Biological: Nivolumab
36 Not yet recruiting Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer
Conditions: Advanced Melanoma;   Triple-Negative Breast Cancer
Interventions: Biological: Imprime PGG;   Drug: Pembrolizumab
37 Not yet recruiting A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab
Conditions: Acral Lentiginous Melanoma;   Mucosal Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
38 Recruiting Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab
Condition: Malignant Melanoma Stage III
Interventions: Drug: Ipilimumab;   Drug: Nivolumab;   Procedure: Surgery;   Procedure: Blood for PBMCs;   Procedure: Biopsies
39 Not yet recruiting A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Condition: Metastatic Melanoma
Intervention: Drug: PLX3397
40 Not yet recruiting Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases
Conditions: Melanoma;   Brain Metastases
Interventions: Drug: Dabrafenib;   Drug: Trametinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.